Imaging Technologies and Transdermal Delivery in Skin Disorders

CHAPTER 1: SKIN STRUCTURE AND BIOLOGYCHAPTER 2: WOUND HEALING AND ITS IMAGINGCHAPTER 3: COMMON SKIN DISEASES - CHRONIC INFLAMMATORY AND AUTOIMMUNE DISORDERSCHAPTER 4: COMMON SKIN DISEASES - AUTOIMMUNE BLISTERING DISORDERSCHAPTER 5: COMMON SKIN DISEASES -SKIN CANCERCHAPTER 6: PRECLINICAL MODELS FOR DRUG SCREENING AND TARGET VALIDATIONCHAPTER 7: SKIN TISSUE ENGINEERING WITH NANOSTRUCTURED MATERIALSCHAPTER 8: TOPICAL/TRANSDERMAL DELIVERY WITH CHEMICAL ENHANCERS AND NANOPARTICLESCHAPTER 9: NEEDLE FREE JET INJECTORS FOR DERMAL AND TRANSDERMAL DELIVERY OF ACTIVESCHAPTER 10: MICRONEEDLES FOR TRANSDERMAL DRUG DELIVERYCHAPTER 11: ULTRASOUND ENHANCED TRANSDERMAL DRUG DELIVERYCHAPTER 12: IONTOPHORESIS ENHANCED TRANSDERMAL DRUG DELIVERYCHAPTER 13: ULTROSOUND IMAGING IN DERMATOLOGYCHAPTER 14: QUANTITATIVE MAGNETIC RESONANCE IMAGING OF THE SKIN: IN VITRO AND IN VIVO APPLICATIONSCHAPTER 15: HIGH-RESOLUTION OPTICAL COHERENCE TOMOGRAPHY (oct) FOR SKIN IMAGINGCHAPTER 16: PHOTOACOUSTIC IMAGING OF SKINCHAPTER 17: LASER SPECKLE TECHNIQUES FOR FLOW MONITORING IN SKIN

Dr. Chenjie Xu is an assistant professor at School of Chemical and Biomedical Engineering (SCBE) at Nanyang Technological University (NTU), Singapore. He received his PhD. (2009) from Brown University under Prof. Shouheng Sun and did his postdoc under Prof. Jeffrey Karp at Brigham and Women's Hospital. He is interested in developing transdermal technologies for diagnosis and treatment of skin diseases especially abnormal scar. He has published more than 90 peer-reviewed articles.Dr. Xiaomeng Wang currently serves as an Assistant Professor at NTU, Principal Investigator at IMCB, Honorary Lecturer at UCL, Adjunct Research Scientist at SERI. She is an innovative scientist with extensive expertise in the field of vascular biology pertaining to diseases of the skin. Her recent study led to the identification of a novel angiogenic factor, LRG1 and the LRG1 blocking antibody is currently in Phase I clinical trial as a combined treatment strategy with Lucentis in patients with neovascular AMD. Her current research focuses on the role of LRG1 in fibrovascular proliferation and scaring of the skin and her work had been published in high impact journals including Nature and Nature protocols. Over the last few years, her laboratory has established and developed a number of state-of-the-art in vitro, ex vivo, in vivo assay systems that are suitable for detailed characterization of the temporal and spatial interactions between different types of cells involved in sprouting angiogenesis and tissue fibrosis. Dr. Wang is also the co-inventor on two international patents relating to LRG1 and its potential as therapeutic target for vasoproliferative conditions and cancerDr. Manojit Pramanik received his Ph.D. degree (2010) in Biomedical Engineering from Washington University in St. Louis, St. Louis, USA under the tutelage of Dr. Lihong Wang. He joined the School of Chemical and Biomedical Engineering (SCBE) at Nanyang Technological University (NTU), Singapore as Assistant Professor in